Literature DB >> 20566941

Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir.

Patrick Unemori, Kieron S Leslie, Toby Maurer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20566941      PMCID： PMC4636204          DOI： 10.1001/archdermatol.2010.128

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  8 in total

1.  Histopathological and bacteriological findings in prurigo nodularis.

Authors:  J O Mattila; M Vornanen; M L Katila
Journal:  Acta Derm Venereol       Date:  1997-01       Impact factor: 4.437

Review 2.  Prurigo nodularis: a review.

Authors:  Michael R Lee; Stephen Shumack
Journal:  Australas J Dermatol       Date:  2005-11       Impact factor: 2.875

3.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Authors:  Beatriz Grinsztejn; Bach-Yen Nguyen; Christine Katlama; Jose M Gatell; Adriano Lazzarin; Daniel Vittecoq; Charles J Gonzalez; Joshua Chen; Charlotte M Harvey; Robin D Isaacs
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

4.  Helicobacter pylori and prurigo nodularis.

Authors:  S Neri; D Ierna; R A D'Amico; G Giarratano; C Leotta
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

5.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

Authors:  John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Journal:  AIDS       Date:  2007-11-12       Impact factor: 4.177

6.  Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience.

Authors:  Pedro C Queiroz Zancanaro; Laura Y McGirt; Adam J Mamelak; Ruby H-N Nguyen; Ciro R Martins
Journal:  J Am Acad Dermatol       Date:  2006-02-23       Impact factor: 11.527

7.  Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

8.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321
  8 in total
  1 in total

Review 1.  Inflammatory dermatoses in human immunodeficiency virus.

Authors:  Taru Garg; Sarita Sanke
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jul-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.